We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 84

Otsuka successful in stay application: Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd 2015 FCA 848
  • King & Wood Mallesons
  • Australia
  • August 26 2015

Further to our post of 7 July 2015, the proceedings brought by Otsuka and Bristol Myers Squibb (the "exclusive licensee" of Otsuka's patents for


Full Court warns against dangerous affliction of parameteritis (and confirms invalidity of aripiprazole patent)
  • King & Wood Mallesons
  • Australia
  • August 26 2016

On Wednesday the Full Court of the Federal Court of Australia handed down a decision in which it upheld Justice Yates' findings that Otsuka's patent


Just genes? Lessons from the Myriad litigation
  • King & Wood Mallesons
  • Australia
  • August 19 2013

Last month the United States Supreme Court ruled that certain naturally occurring DNA sequences (the BRCA1 and BRCA2 genes, mutations in which are


Competition regulators continue their campaign against pharmaceutical companies
  • King & Wood Mallesons
  • Australia, USA
  • June 1 2011

Last month, the US Federal Trade Commission (FTC) released its findings on reverse payment settlements between pharmaceutical companies in the 2010 US fiscal year


European Court of Justice says no to patents requiring the destruction of a human embryo - an Australian perspective
  • King & Wood Mallesons
  • Australia, European Union
  • October 20 2011

Article 6(2)(c) of the European Biotech Directive excludes inventions which use human embryos for industrial or commercial purposes from patentability


Breaking news: hard Medicine for group members to take - Full Court overturns decision in VIOXX class action
  • King & Wood Mallesons
  • Australia, USA
  • October 12 2011

The Full Court of the Federal Court of Australia has overturned the 2010 decision that marked the first successful class action ruling in the world in relation to arthritis drug VIOXX


European Commission ups the cost of paying for delay
  • King & Wood Mallesons
  • Australia, European Union, USA
  • August 13 2012

On 25 July 2012, the EC alleged that Danish pharmaceutical company Lundbeck violated EU antitrust rules by colluding to prevent other pharma companies from marketing generic versions of its best-seller antidepressant, citalopram


Experimental evidence comply with the rules or risk inadmissibility
  • King & Wood Mallesons
  • Australia
  • March 22 2013

By refusing to allow Generic Health to adduce experimental evidence in a patent case currently being heard in the Federal Court, Justice Jagot has


Those drugs cost how much?? Chemist warehouse price list misleading but not for the reasons you might think
  • King & Wood Mallesons
  • Australia
  • October 29 2012

Last Monday the Supreme Court of Queensland held that a price list published by various Chemist Warehouse pharmacies in Cairns, Nerang, Coolangatta and other parts of Queensland was likely to mislead or deceive and therefore contravene clause 18 of the Australian Consumer Law (Competition and Consumer Act 2010 (Cth), schedule 2, section 18


Australian court decides important gene patenting question isolated genetic material patentable subject matter
  • King & Wood Mallesons
  • Australia
  • February 15 2013

Earlier today, the Federal Court rejected a claim brought by Cancer Voices Australia that isolated genetic material (DNA or RNA) that is naturally